Company news

CRISPR Therapeutics AG news in 2024

CRISPR Therapeutics AG's news releases, calls and decks from 2024, newest first.

View company

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

December 8, 2024

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

November 13, 2024

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

November 6, 2024

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

November 4, 2024

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

August 4, 2024

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

May 22, 2024

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

May 8, 2024

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 7, 2024

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

May 7, 2024

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

April 21, 2024

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

April 2, 2024

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

March 31, 2024

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

February 20, 2024

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

February 14, 2024

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

February 12, 2024

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

February 12, 2024

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

January 15, 2024

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

January 7, 2024

CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Decks in 2024